Citations

Clear

9383 citation(s) found for "Thomas, PS".

Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, Manthos G., Umpleby, A. Margot , Sönksen, Peter H. , Martin, Finbarr C. , Nair, K. Sreekumaran

Mayo Clinic

Endocrine Reviews | June 6, 2012 | Volume: 33 | Issue: 3 | Pages: 314-377

10.1210/er.2012-1002 | PMID 22433122 Get It

Improving physical function and mobility in a continuously expanding elderly population emerges as a high priority of medicine today. Muscle mass, strength/power, and maximal exercise capacity are major determinants of physical function, and all decline with aging. This contributes to the incidence of frailty and disability observed in older men. Furthermore, it facilitates the accumulation of body fat and development of insulin resistance.Muscle adaptation to exercise is strongly influenced by anabolic endocrine hormones and local load-sensitive autocrine/paracrine growth factors. GH, IGF-I, and testosterone (T) are directly involved in muscle adaptation to exercise because they promote muscle protein synthesis, whereas T and locally expressed IGF-I have been reported to activate muscle stem cells. Although exercise programs improve physical function, in the long-term most older men fail to comply. The GH/IGF-I axis and T levels decline markedly with aging, whereas accumulating evidence supports their indispensable role in maintaining physical function integrity.Several studies have reported that the administration of T improves lean body mass and maximal voluntary strength in healthy older men. On the other hand, most studies have shown that administration of GH alone failed to improve muscle strength despite amelioration of the detrimental somatic changes of aging. Both GH and T are anabolic agents that promote muscle protein synthesis and hypertrophy but work through separate mechanisms, and the combined administration of GH and T, albeit in only a few studies, has resulted in greater efficacy than either hormone alone. Although it is clear that this combined approach is effective, this review concludes that further studies are needed to assess the long-term efficacy and safety of combined hormone replacement therapy in older men before the medical rationale of prescribing hormone replacement therapy for combating the sarcopenia of aging can be established.
Guideline for the diagnosis and management of myelofibrosis
Reilly, John T., Beer, Philip , Butt, Nauman M., Conneally, Eibhlin , Duncombe, Andrew , Green, Anthony R. , Michaeel, N. George, Gilleece, Maria , Hall, Georgina , Knapper, Steven , Mead, Adam J. , Sekhar, Mallika , Wilkins, Bridget S., Harrison, Claire , McMullin, Mary Frances , Mesa, Ruben A. , Mead, Adam J , Knapper, Steven

Mayo Clinic

British Journal of Haematology | June 1, 2012 | Volume: 158 | Issue: 4 | Pages: 453-471

10.1111/j.1365-2141.2012.09179.x | PMID 22651893 Get It

Summary The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK ‐based medical experts, together with a contribution from a single expert from the USA . MEDLINE and EMBASE were searched systematically for publications in E nglish from 1966 until A ugust 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato‐oncology Task Forces of the British Committee for Standards in Haematology ( BCSH ). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH ; the ‘ GRADE ‘ system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post‐polycythaemic myelofibrosis (post‐ PV MF ) and post‐thrombocythemic myelofibrosis (post‐ ET MF ) in both adult and paediatric patients.
Interventions to Increase Enrollment in a Large Multicenter Phase 3 Trial of Carotid Stenting Vs. Endarterectomy
Longbottom, Mary, Roberts, Jamie , Tom, MeeLee , Hughes, Susan , Howard, Virginia J. , Sheffet, Alice J., Brott, Thomas G. , Investigators, for the CREST, Meschia, James F. , Investigators, for the CREST, Howard, Virginia J

Mayo Clinic

International Journal of Stroke | May 28, 2012 | Volume: 7 | Issue: 6 | Pages: 447-453

10.1111/j.1747-4949.2012.00833.x | PMID 22631861 Get It

Background Randomized clinical trials often encounter slow enrollment. Failing to meet sample size requirements has scientific, financial, and ethical implications. Aims We report interventions used to accelerate recruitment in a large multicenter clinical trial that was not meeting prespecified enrollment commitments. Methods The Carotid Revascularization Endarterectomy vs. Stenting Trial began randomization in December 2000. To accelerate enrollment, multiple recruitment tactics were initiated, which included expanding the number of sites, hiring a recruitment director (May 2003), broadening eligibility criteria (April 2005), branding with a study logo, Web site, and recruitment materials, increasing site visits by study leadership, sending e-mails to the site teams after every enrollment, distributing electronic newsletters, and implementing investigator and coordinator conferences. Results From December 2000 through May 2003, 14 sites became active (54 patients randomized), from June 2003 through April 2005, 44 sites were added (404 patients randomized), and from May 2005 through July 2008, 54 sites were added (2044 patients randomized). During these time intervals, the number of patients enrolled per site per year was 1.5, 3.6, and 5.6. For the single years 2004 to 2008, the mean monthly randomization rates per year were 19.7, 38.1, 56.4, 53.0, and 54.7 (annualized), respectively. Enrollment was highest after recruitment tactics were implemented: 677 patients in 2006, 636 in 2007, and 657 in 2008 (annualized). The prespecified sample size of 2502 patients, 47% asymptomatic, was accomplished on July 2008. Conclusions Aggressive recruitment tactics and investment in a full-time recruitment director who can lead implementation may be effective in accelerating recruitment in multicenter trials.
Altering the Landscape for Women in Clinical Chemistry: Perspectives from Multigenerational Leaders
Haymond, Shannon, Saenger, Amy K., Free, Helen M., Hicks, Jocelyn M., Horvath, Andrea R. , Fantz, Corinne R. , Horváth, Rita , Huestis, Marilyn Ann

Mayo Clinic

Clinical Chemistry | May 23, 2012 | Volume: 58 | Issue: 7 | Pages: 1082-1085

10.1373/clinchem.2011.174284 | PMID 22623746 Get It

Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system
Hirano, Ikuo , Moy, Nelson, Thomas, Colleen S. , Gonsalves, Nirmala , Achem, Sami R., Heckman, Michael G.

Mayo Clinic

Gut | May 22, 2012 | Volume: 62 | Issue: 4 | Pages: 489-495

10.1136/gutjnl-2011-301817 | PMID 22619364 Get It

Objective Abnormalities are commonly identified during endoscopy in eosinophilic oesophagitis (EoE). There is no standardised classification to describe these features. This study aimed to evaluate the interobserver agreement of a grading system for the oesophageal features of EoE. Method The proposed system incorporated the grading of four major oesophageal features (rings, furrows, exudates, oedema) and the presence of additional features of narrow calibre oesophagus, feline oesophagus, stricture and crepe paper oesophagus. Endoscopic videos from 25 patients with EoE and controls were reviewed by 21 gastroenterologists. Interobserver agreement was assessed by estimating multi-rater κ and the proportion of pairwise agreement. Results Using the original grading system, agreement for rings, furrows and exudates was moderate (κ=0.38–0.46, 56–65% agreement) but poor for oedema (κ=0.23, 51% agreement). Identification of narrow calibre oesophagus had fair agreement (κ=0.30, 74% agreement) while feline oesophagus had poor agreement (κ=0.15, 68% agreement). After collapsing the severity grading for oedema and furrows and eliminating poorly performing features of feline oesophagus and narrow calibre oesophagus, a modified grading system demonstrated good agreement for the four major features of EoE (κ=0.40–0.54, 71–81% agreement) and additional features of stricture and crepe paper oesophagus (κ=0.52 and 0.58, 79% and 92% agreement). Conclusions The proposed system for endoscopically-identified oesophageal features of EoE defines common nomenclature and severity scores for the assessment of EoE disease activity. The system has good interobserver agreement among practising and academic gastroenterologists.
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set
Thomas, David M. , Yothers, Greg , Green, Erin , Blanke, Charles D. , Labianca, Roberto , Shi, Qian , Gramont, Aimery de , Sargent, Daniel J. , Hubbard, Joleen M. , O’Connell, Michael J. , Bleyer, Archie , Sargent, Daniel J , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | May 21, 2012 | Volume: 30 | Issue: 19 | Pages: 2334-2339

10.1200/jco.2011.41.1975 | PMID 22614981 Get It

Purpose Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. Patients and Methods Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. Results One thousand seven hundred fifty-eight patients (5.2%) were younger than 40 years, 5,817 patients (17.3%) were younger than 50 years, and only 299 patients (0.9%) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. Conclusion Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria.
Development of a Multidisciplinary, Multicampus Subspecialty Practice in Endocrine Cancers
Bible, Keith C. , Smallridge, Robert C., Morris, John C., Molina, Julian R. , Copland, John A. , Rubin, Joseph, Menefee, Michael E., Sideras, Kostandinos , Maples, William J., McIver, Bryan, Fatourechi, Vahab , Foote, Robert L. , Garces, Yolanda I. , Kasperbauer, Jan L. , Thompson, Geoffrey B. , Grant, Clive S., Richards, Melanie L. , Sebo, Thomas J., Lloyd, Ricardo V., Eberhardt, Norman L., Casler, John D., Karlin, Nina J. , Westphal, Sydney A., Richardson, Ronald L., Buckner, Jan C. , Erlichman, Charles , Suman, Vera J. , Hay, Ian , Reddi, Honey V. , Sideras, Kostandinos

Mayo Clinic

Journal of Oncology Practice | May 20, 2012 | Volume: 8 | Issue: 3S | Pages: e1s-e5s

10.1200/jop.2011.000496 | PMID 22942830 Get It

The development of subspecialty tumor groups for uncommon malignancies represents an effective approach to building experience, increasing patient volumes and referrals, and fostering development of increased therapeutic options and clinical trials for patients afflicted with otherwise historically neglected cancers.
Positional Periodic Alternating Vertical Nystagmus with PCA-Tr Antibodies in Hodgkin Lymphoma
Eggers, Scott D.Z. , Pittock, Sean J. , Shepard, Neil T., Neff, Brian A., Klebig, Robin, Habermann, Thomas M. , Pittock, S J

Mayo Clinic

Neurology | May 17, 2012 | Volume: 78 | Issue: 22 | Pages: 1800-1802

10.1212/wnl.0b013e3182583085 | PMID 22592362 Get It

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
He, Li-Zhen, Thomas, Lawrence J. , Widger, Jennifer, Weidlick, Jeffrey, Crocker, Andrea, O’Neill, Thomas J. , Storey, James R., Glennie, Martin J. , Grote, Deanna M., Ansell, Stephen M. , Marsh, Henry C. , Keler, Tibor , Vitale, Laura A.

Mayo Clinic

Clinical Cancer Research | May 16, 2012 | Volume: 18 | Issue: 14 | Pages: 3812-3821

10.1158/1078-0432.ccr-11-3308 | PMID 22589397 Get It

AbstractPurpose: The TNF receptor superfamily member CD27 is best known for its important role in T-cell immunity but is also recognized as a cell-surface marker on a number of B- and T-cell malignancies. In this article, we describe a novel human monoclonal antibody (mAb) specific for CD27 with properties that suggest a potential utility against malignancies that express CD27.Experimental Design: The fully human mAb 1F5 was generated using human Ig transgenic mice and characterized by analytical and functional assays in vitro. Severe combined immunodeficient (SCID) mice inoculated with human CD27-expressing lymphoma cells were administered 1F5 to investigate direct antitumor effects. A pilot study of 1F5 was conducted in non-human primates to assess toxicity.Results: 1F5 binds with high affinity and specificity to human and macaque CD27 and competes with ligand binding. 1F5 activates T cells only in combination with T-cell receptor stimulation and does not induce proliferation of primary CD27-expressing tumor cells. 1F5 significantly enhanced the survival of SCID mice bearing Raji or Daudi tumors, which may be mediated through direct effector mechanisms such as antibody-dependent cellular cytotoxicity. Importantly, administration of up to 10 mg/kg of 1F5 to cynomolgus monkeys was well tolerated without evidence of significant toxicity or depletion of circulating lymphocytes.Conclusions: Collectively, the data suggest that the human mAb 1F5, which has recently entered clinical development under the name CDX-1127, may provide direct antitumor activity against CD27-expressing lymphoma or leukemia, independent of its potential to enhance immunity through its agonistic properties. Clin Cancer Res; 18(14); 3812–21. ©2012 AACR.
Migraine practice patterns among neurologists
Bigal, ME, Rush, Steven R., Yenkosky, J. P., Liberman, Joshua N. , Bartleson, J. D., Silberstein, Stephen D., Lipton, Richard B.

Mayo Clinic

Neurology | May 14, 2012 | Volume: 62 | Issue: 11 | Pages: 1926-1931

10.1212/wnl.62.11.1926 | PMID 15184590 Get It